Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease

Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease

A therapeutic vaccine for human Chagas disease is under development by the Sabin Vaccine Institute Product Development Partnership. The aim of the vaccine is to significantly reduce the parasite burden of Trypanosoma cruzi in humans, either as a standalone product or in combination with conventional...

Full description

Bibliographic Details
Main Authors: Christopher A. Seid, Kathryn M. Jones, Jeroen Pollet, Brian Keegan, Elissa Hudspeth, Molly Hammond, Junfei Wei, C. Patrick McAtee, Leroy Versteeg, Amanda Gutierrez, Zhuyun Liu, Bin Zhan, Jonathan L. Respress, Ulrich Strych, Maria Elena Bottazzi, Peter J. Hotez
Format: Article
Language:English
Published: Taylor & Francis Group 2017-03-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
antigen
chagas disease
pre-clinical testing
production
vaccine
Online Access:http://dx.doi.org/10.1080/21645515.2016.1242540

Internet

http://dx.doi.org/10.1080/21645515.2016.1242540

Similar Items